EA201690731A1 - Анализ igfbp7, имеющий улучшенную характеристику в биологических образцах - Google Patents

Анализ igfbp7, имеющий улучшенную характеристику в биологических образцах

Info

Publication number
EA201690731A1
EA201690731A1 EA201690731A EA201690731A EA201690731A1 EA 201690731 A1 EA201690731 A1 EA 201690731A1 EA 201690731 A EA201690731 A EA 201690731A EA 201690731 A EA201690731 A EA 201690731A EA 201690731 A1 EA201690731 A1 EA 201690731A1
Authority
EA
Eurasian Patent Office
Prior art keywords
analysis
igfbp7
improved characteristics
biological specimens
improved
Prior art date
Application number
EA201690731A
Other languages
English (en)
Russian (ru)
Inventor
Рави А. Виджаендран
Сриватса Венкатасуббарао
Original Assignee
Астьют Медикал, Инк.
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Астьют Медикал, Инк. filed Critical Астьют Медикал, Инк.
Publication of EA201690731A1 publication Critical patent/EA201690731A1/ru

Links

Classifications

    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07KPEPTIDES
    • C07K16/00Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
    • C07K16/18Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • GPHYSICS
    • G01MEASURING; TESTING
    • G01NINVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N33/00Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
    • G01N33/48Biological material, e.g. blood, urine; Haemocytometers
    • G01N33/50Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
    • G01N33/53Immunoassay; Biospecific binding assay; Materials therefor
    • G01N33/543Immunoassay; Biospecific binding assay; Materials therefor with an insoluble carrier for immobilising immunochemicals
    • G01N33/54306Solid-phase reaction mechanisms
    • GPHYSICS
    • G01MEASURING; TESTING
    • G01NINVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N33/00Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
    • G01N33/48Biological material, e.g. blood, urine; Haemocytometers
    • G01N33/50Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
    • G01N33/53Immunoassay; Biospecific binding assay; Materials therefor
    • G01N33/558Immunoassay; Biospecific binding assay; Materials therefor using diffusion or migration of antigen or antibody
    • GPHYSICS
    • G01MEASURING; TESTING
    • G01NINVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N33/00Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
    • G01N33/48Biological material, e.g. blood, urine; Haemocytometers
    • G01N33/50Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
    • G01N33/68Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving proteins, peptides or amino acids
    • G01N33/6893Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving proteins, peptides or amino acids related to diseases not provided for elsewhere
    • GPHYSICS
    • G01MEASURING; TESTING
    • G01NINVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N33/00Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
    • G01N33/48Biological material, e.g. blood, urine; Haemocytometers
    • G01N33/50Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
    • G01N33/74Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving hormones or other non-cytokine intercellular protein regulatory factors such as growth factors, including receptors to hormones and growth factors
    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07KPEPTIDES
    • C07K2317/00Immunoglobulins specific features
    • C07K2317/10Immunoglobulins specific features characterized by their source of isolation or production
    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07KPEPTIDES
    • C07K2317/00Immunoglobulins specific features
    • C07K2317/30Immunoglobulins specific features characterized by aspects of specificity or valency
    • C07K2317/34Identification of a linear epitope shorter than 20 amino acid residues or of a conformational epitope defined by amino acid residues
    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07KPEPTIDES
    • C07K2317/00Immunoglobulins specific features
    • C07K2317/50Immunoglobulins specific features characterized by immunoglobulin fragments
    • C07K2317/56Immunoglobulins specific features characterized by immunoglobulin fragments variable (Fv) region, i.e. VH and/or VL
    • GPHYSICS
    • G01MEASURING; TESTING
    • G01NINVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N2333/00Assays involving biological materials from specific organisms or of a specific nature
    • G01N2333/435Assays involving biological materials from specific organisms or of a specific nature from animals; from humans
    • G01N2333/46Assays involving biological materials from specific organisms or of a specific nature from animals; from humans from vertebrates
    • G01N2333/47Assays involving proteins of known structure or function as defined in the subgroups
    • G01N2333/4701Details
    • G01N2333/4745Insulin-like growth factor binding protein
    • GPHYSICS
    • G01MEASURING; TESTING
    • G01NINVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N2800/00Detection or diagnosis of diseases
    • G01N2800/34Genitourinary disorders
    • G01N2800/347Renal failures; Glomerular diseases; Tubulointerstitial diseases, e.g. nephritic syndrome, glomerulonephritis; Renovascular diseases, e.g. renal artery occlusion, nephropathy

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Engineering & Computer Science (AREA)
  • Immunology (AREA)
  • Molecular Biology (AREA)
  • Biomedical Technology (AREA)
  • Urology & Nephrology (AREA)
  • Hematology (AREA)
  • Medicinal Chemistry (AREA)
  • Biochemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Pathology (AREA)
  • Physics & Mathematics (AREA)
  • Analytical Chemistry (AREA)
  • Biotechnology (AREA)
  • Cell Biology (AREA)
  • General Physics & Mathematics (AREA)
  • Microbiology (AREA)
  • Food Science & Technology (AREA)
  • Organic Chemistry (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Biophysics (AREA)
  • Genetics & Genomics (AREA)
  • Endocrinology (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Peptides Or Proteins (AREA)
  • Micro-Organisms Or Cultivation Processes Thereof (AREA)
  • Investigating Or Analysing Biological Materials (AREA)
  • Preparation Of Compounds By Using Micro-Organisms (AREA)
  • Apparatus Associated With Microorganisms And Enzymes (AREA)
EA201690731A 2013-11-06 2014-11-06 Анализ igfbp7, имеющий улучшенную характеристику в биологических образцах EA201690731A1 (ru)

Applications Claiming Priority (4)

Application Number Priority Date Filing Date Title
US201361900942P 2013-11-06 2013-11-06
US201462054324P 2014-09-23 2014-09-23
US201462064380P 2014-10-15 2014-10-15
PCT/US2014/064327 WO2015069880A1 (en) 2013-11-06 2014-11-06 Assays for igfbp7 having improved performance in biological samples

Publications (1)

Publication Number Publication Date
EA201690731A1 true EA201690731A1 (ru) 2016-10-31

Family

ID=53042071

Family Applications (1)

Application Number Title Priority Date Filing Date
EA201690731A EA201690731A1 (ru) 2013-11-06 2014-11-06 Анализ igfbp7, имеющий улучшенную характеристику в биологических образцах

Country Status (12)

Country Link
US (3) US9822172B2 (OSRAM)
EP (2) EP3066221A4 (OSRAM)
JP (4) JP2017501211A (OSRAM)
KR (1) KR102404285B1 (OSRAM)
CN (1) CN105793439B (OSRAM)
AU (1) AU2014346695B2 (OSRAM)
BR (1) BR112016010106A2 (OSRAM)
CA (2) CA2929547C (OSRAM)
EA (1) EA201690731A1 (OSRAM)
HK (1) HK1221490A1 (OSRAM)
MX (1) MX375701B (OSRAM)
WO (1) WO2015069880A1 (OSRAM)

Families Citing this family (14)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
NZ592358A (en) 2008-10-21 2013-05-31 Astute Medical Inc Methods and compositions for diagnosis and prognosis of renal injury and renal failure using tissue inhibitor of metalloproteinase 2 (timp-2)
EP3112871B1 (en) 2009-12-20 2020-07-29 Astute Medical, Inc. Methods and compositions for diagnosis and prognosis of renal injury and renal failure
CA2804297A1 (en) 2010-06-23 2011-12-29 Astute Medical, Inc. Methods and compositions for diagnosis and prognosis of renal injury and renal failure
EP3540440B1 (en) 2011-12-08 2022-09-28 Astute Medical, Inc. Methods and uses for evaluating renal injury and renal status
EP3361255B1 (en) 2013-01-17 2020-03-11 Astute Medical, Inc. Methods and compositions for diagnosis and prognosis of renal injury and renal failure
JP2016540759A (ja) 2013-12-03 2016-12-28 アスチュート メディカル,インコーポレイテッド 腎損傷および腎不全の診断および予後のための方法および組成物
EP3281011B1 (en) 2015-04-09 2024-06-05 Astute Medical, Inc. Methods and compositions for diagnosis and prognosis of renal injury and renal failure
JP6859334B2 (ja) * 2015-10-08 2021-04-14 エフ.ホフマン−ラ ロシュ アーゲーF. Hoffmann−La Roche Aktiengesellschaft 手術前に測定した際にakiのリスクを予測するためのigfbp7
CA3026502A1 (en) 2016-06-06 2017-12-14 Astute Medical, Inc. Management of acute kidney injury using insulin-like growth factor-binding protein 7 and tissue inhibitor of metalloproteinase 2
EP3577458A4 (en) 2017-02-06 2021-04-07 Astute Medical, Inc. METHODS AND COMPOSITIONS FOR DIAGNOSIS AND PREDICTION OF RENAL LESION AND RENAL INSUFFICIENCY
US11718682B2 (en) 2017-04-05 2023-08-08 Astute Medical, Inc. Assays for TIMP2 having improved performance in biological samples
SG11202011502VA (en) 2018-05-24 2020-12-30 Renibus Therapeutics Inc Methods of treating patients at risk for renal injury and renal failure
WO2020234482A1 (en) * 2019-05-21 2020-11-26 Universität Zürich MAPKi RESISTANCE SIGNATURES
KR102533791B1 (ko) * 2022-09-15 2023-05-18 경북대학교 산학협력단 비색법 신호형질 복합체, 이를 이용하는 신장질환 진단용 키트 및 진단법

Family Cites Families (47)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
DE3029579C2 (de) 1980-08-05 1985-12-12 Boehringer Mannheim Gmbh, 6800 Mannheim Verfahren und Mittel zur Abtrennung von Plasma oder Serum aus Vollblut
US5807715A (en) 1984-08-27 1998-09-15 The Board Of Trustees Of The Leland Stanford Junior University Methods and transformed mammalian lymphocyte cells for producing functional antigen-binding protein including chimeric immunoglobulin
US5223409A (en) 1988-09-02 1993-06-29 Protein Engineering Corp. Directed evolution of novel binding proteins
US5530101A (en) 1988-12-28 1996-06-25 Protein Design Labs, Inc. Humanized immunoglobulins
US5939272A (en) 1989-01-10 1999-08-17 Biosite Diagnostics Incorporated Non-competitive threshold ligand-receptor assays
US5028535A (en) 1989-01-10 1991-07-02 Biosite Diagnostics, Inc. Threshold ligand-receptor assay
US5413923A (en) 1989-07-25 1995-05-09 Cell Genesys, Inc. Homologous recombination for universal donor cells and chimeric mammalian hosts
US5859205A (en) 1989-12-21 1999-01-12 Celltech Limited Humanised antibodies
ATE139258T1 (de) 1990-01-12 1996-06-15 Cell Genesys Inc Erzeugung xenogener antikörper
US5922615A (en) 1990-03-12 1999-07-13 Biosite Diagnostics Incorporated Assay devices comprising a porous capture membrane in fluid-withdrawing contact with a nonabsorbent capillary network
US5166051A (en) 1990-08-08 1992-11-24 Genesis Labs, Inc. Membranes, membrane overlays for exclusion of erythrocytes, and method for immunoassay of whole blood analytes
US5545806A (en) 1990-08-29 1996-08-13 Genpharm International, Inc. Ransgenic non-human animals for producing heterologous antibodies
AU8507191A (en) 1990-08-29 1992-03-30 Genpharm International, Inc. Transgenic non-human animals capable of producing heterologous antibodies
US5661016A (en) 1990-08-29 1997-08-26 Genpharm International Inc. Transgenic non-human animals capable of producing heterologous antibodies of various isotypes
US5814318A (en) 1990-08-29 1998-09-29 Genpharm International Inc. Transgenic non-human animals for producing heterologous antibodies
US5625126A (en) 1990-08-29 1997-04-29 Genpharm International, Inc. Transgenic non-human animals for producing heterologous antibodies
US5633425A (en) 1990-08-29 1997-05-27 Genpharm International, Inc. Transgenic non-human animals capable of producing heterologous antibodies
JPH05504841A (ja) 1990-09-14 1993-07-22 バイオサイト・ダイアグノスティックス・インコーポレイテッド リガンドレセプター及びリガンドのコンプレックスに対する抗体及びリガンド―レセプターアッセーでのそれらの用途
GB9109645D0 (en) 1991-05-03 1991-06-26 Celltech Ltd Recombinant antibodies
US5955377A (en) 1991-02-11 1999-09-21 Biostar, Inc. Methods and kits for the amplification of thin film based assays
CA2107899A1 (en) 1991-04-10 1992-10-11 Gunars Edwin Valkirs Novel conjugates and assays for simultaneous detection of multiple ligands
JPH06506688A (ja) 1991-04-10 1994-07-28 バイオサイト・ダイアグノスティックス・インコーポレイテッド クロストークインヒビターおよびその使用
WO1994004679A1 (en) 1991-06-14 1994-03-03 Genentech, Inc. Method for making humanized antibodies
EP0940468A1 (en) 1991-06-14 1999-09-08 Genentech, Inc. Humanized antibody variable domain
US6019944A (en) 1992-05-21 2000-02-01 Biosite Diagnostics, Inc. Diagnostic devices and apparatus for the controlled movement of reagents without membranes
US6143576A (en) 1992-05-21 2000-11-07 Biosite Diagnostics, Inc. Non-porous diagnostic devices for the controlled movement of reagents
US5494829A (en) 1992-07-31 1996-02-27 Biostar, Inc. Devices and methods for detection of an analyte based upon light interference
US5824799A (en) 1993-09-24 1998-10-20 Biosite Diagnostics Incorporated Hybrid phthalocyanine derivatives and their uses
EP0822830B1 (en) 1995-04-27 2008-04-02 Amgen Fremont Inc. Human anti-IL-8 antibodies, derived from immunized xenomice
EP0823941A4 (en) 1995-04-28 2001-09-19 Abgenix Inc HUMAN ANTIBODIES DERIVED FROM IMMUNIZED XENO MOUSES
US6391265B1 (en) 1996-08-26 2002-05-21 Biosite Diagnostics, Inc. Devices incorporating filters for filtering fluid samples
US6113855A (en) 1996-11-15 2000-09-05 Biosite Diagnostics, Inc. Devices comprising multiple capillarity inducing surfaces
EP1500329B1 (en) 1996-12-03 2012-03-21 Amgen Fremont Inc. Human antibodies that specifically bind human TNF alpha
US6045899A (en) 1996-12-12 2000-04-04 Usf Filtration & Separations Group, Inc. Highly assymetric, hydrophilic, microfiltration membranes having large pore diameters
US5947124A (en) 1997-03-11 1999-09-07 Biosite Diagnostics Incorporated Diagnostic for determining the time of a heart attack
US6057098A (en) 1997-04-04 2000-05-02 Biosite Diagnostics, Inc. Polyvalent display libraries
US7109030B2 (en) * 2000-03-31 2006-09-19 Nuvelo, Inc. Methods of therapy and diagnosis using insulin-like growth factor binding protein-like polypeptides and polynucleotides
US20020132983A1 (en) 2000-11-30 2002-09-19 Junghans Richard P. Antibodies as chimeric effector cell receptors against tumor antigens
JP2008541017A (ja) 2005-04-29 2008-11-20 ベックマン コールター インコーポレイテッド 側方流動蛍光免疫測定法
DK1904104T3 (da) * 2005-07-08 2013-11-11 Biogen Idec Inc SP35-antistoffer og anvendelser heraf
DK2115477T3 (en) * 2007-01-25 2015-08-10 Hoffmann La Roche USE OF IGFBP-7 IN THE EVIDENCE OF HEART FAILURE
EP2340262B1 (en) * 2008-10-14 2017-04-05 National Research Council Canada Formulations targeting igfbp7 for diagnosis and therapy of cancer
MX2011011670A (es) * 2009-05-01 2011-11-18 Abbott Lab Inmunoglobulinas de dominio variable dual y usos de las mismas.
EP3112871B1 (en) 2009-12-20 2020-07-29 Astute Medical, Inc. Methods and compositions for diagnosis and prognosis of renal injury and renal failure
PL2666872T3 (pl) * 2010-02-05 2016-10-31 Sposoby i kompozycje do diagnozowania i prognozowania uszkodzenia nerek i niewydolności nerek
CN103260646B (zh) * 2010-08-27 2016-01-13 施特姆森特克斯股份有限公司 Notum蛋白调节剂和使用方法
KR20140091038A (ko) * 2011-11-03 2014-07-18 톨러러 세러퓨틱스 인코포레이티드 T-세포 반응의 선택적 억제를 위한 항체 및 방법

Also Published As

Publication number Publication date
US20180066045A1 (en) 2018-03-08
KR102404285B1 (ko) 2022-05-31
US9822172B2 (en) 2017-11-21
AU2014346695B2 (en) 2020-10-15
CN105793439A (zh) 2016-07-20
EP3556863A1 (en) 2019-10-23
CN105793439B (zh) 2020-09-04
US10562961B2 (en) 2020-02-18
KR20160068988A (ko) 2016-06-15
MX375701B (es) 2025-03-06
BR112016010106A2 (pt) 2017-12-05
MX2016005834A (es) 2016-11-17
EP3556863B1 (en) 2024-09-18
JP2023052239A (ja) 2023-04-11
CA2929547C (en) 2023-02-28
US20200247879A1 (en) 2020-08-06
JP2020048569A (ja) 2020-04-02
CA3185700A1 (en) 2015-05-14
US20160289308A1 (en) 2016-10-06
EP3066221A4 (en) 2017-09-20
WO2015069880A1 (en) 2015-05-14
HK1221490A1 (zh) 2017-06-02
JP7277623B2 (ja) 2023-05-19
JP2022068143A (ja) 2022-05-09
CA2929547A1 (en) 2015-05-14
EP3066221A1 (en) 2016-09-14
JP2017501211A (ja) 2017-01-12
AU2014346695A1 (en) 2016-06-16

Similar Documents

Publication Publication Date Title
EA201690731A1 (ru) Анализ igfbp7, имеющий улучшенную характеристику в биологических образцах
EA201690185A1 (ru) Анализ timp2, обладающий улучшенной эффективностью в биологическом образце
CL2015002756A1 (es) Moléculas fc biespecíficas
MX377956B (es) Sistemas y métodos para maximización de uso de muestras.
BR112015022490A2 (pt) métodos e composições para classificação de amostras
MX374652B (es) Ensayos para detectar la presencia o la cantidad de un anticuerpo antifármaco.
BR112015007672A2 (pt) anticorpos anti-pd-l1 monoclonais humanos e métodos de uso
WO2014144822A3 (en) Methods and compositions for tagging and analyzing samples
BR112016014022A2 (pt) anticorpos anti-cd3, ácido nucleico isolado, vetor, célula hospedeira, método de produção do anticorpo anti-cd3, imunoconjugado, composição, uso do anticorpo anti-cd3, métodos de tratamento, métodos de intensificação da função imune e kit
EP2953643A4 (en) NON-PLATE DEPLETING AND NON-ERYTHROCYTE DEPLETING CD47 ANTIBODIES AND METHOD FOR USE THEREOF
EA201690617A1 (ru) Комбинирование anti-lag-3-антител и анти-pd-1-антител для лечения опухолей
EA201491599A1 (ru) Антитела к матриксной металлопротеиназе 9
MX377772B (es) Inmunoensayo de canalización de oxígeno luminiscente utilizando tres anticuerpos y metodos de produccion y uso de los mismos.
BR112014008382A2 (pt) anticorpo especificamente ligando a epítope no domínio sema do c-met
AR093984A1 (es) Anticuerpos que se unen a ligando 1 de muerte programada (pd-l1) humano
MX366275B (es) Metodos para detectar y medir la agregacion.
MX362075B (es) Ensayo de combinación de antígeno-anticuerpo del virus de la hepatitis c (vhc) y métodos y composiciones para usarlo.
UY34999A (es) Formulaciones de anticuerpos anti-receptor de prolactina
CR20140382A (es) Anticuerpos anti-lrp5 y metodos de uso
EA201690213A1 (ru) Композиции и способ лечения связанных с комплементом состояний
EA201792289A1 (ru) Способы обнаружения агглютинации и композиции для их осуществления
EA201890078A1 (ru) Антитело
IN2014DN08011A (OSRAM)
EA201400873A1 (ru) Механическая промывка и измерительный прибор для выполнения анализов
BR112016017764A2 (pt) anticorpo antidengue de amplo espectro